News

Article

How the Type of Stent Used Impacts the Duration of DAPT

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of stent used impacts the duration of dual antiplatelet therapy.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of stent used impacts the duration of dual antiplatelet therapy.

This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC